The requirement for cyclin E in c-Myc overexpressing breast cancers

References

• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
   PubMed Web of Science ®Google Scholar
• Alles MC, Gardiner-Garden M, Nott DJ, et al. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the “basal” breast cancer subgroup. PLoS One. 2009;4(3):e4710.
   PubMed Web of Science ®Google Scholar
• Chandriani S, Frengen E, Cowling VH, et al. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One. 2009;4(8):e6693.
   PubMed Web of Science ®Google Scholar
• Gatza ML, Lucas JE, Barry WT, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010;107(15):6994–6999.
   PubMed Web of Science ®Google Scholar
• Green AR, Aleskandarany MA, Agarwal D, et al. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer. 2016;114(8):917–928.
   PubMed Web of Science ®Google Scholar
• Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012;209(4):679–696.
   PubMed Web of Science ®Google Scholar
• Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer. 2010;1(6):629–640.
   PubMedGoogle Scholar
• Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci. 1998;3:d250–68.
   PubMed Web of Science ®Google Scholar
• Jansen-Durr P, Meichle A, Steiner P, et al. Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A. 1993;90(8):3685–3689.
   PubMed Web of Science ®Google Scholar
• Leone G, DeGregori J, Sears R, et al. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387(6631):422–426.
   PubMed Web of Science ®Google Scholar
• Perez-Roger I, Solomon DL, Sewing A, et al. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes. Oncogene. 1997;14(20):2373–2381.
   PubMed Web of Science ®Google Scholar
• Santoni-Rugiu E, Falck J, Mailand N, et al. Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol. 2000 May;20(10):p3497–509.
   PubMed Web of Science ®Google Scholar
• Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene. 2005;24(17):2776–2786.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–166.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18(22):2699–2711.
   PubMed Web of Science ®Google Scholar
• Geng Y, Whoriskey W, Park MY, et al. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell. 1999;97(6):767–777.
   PubMed Web of Science ®Google Scholar
• Chen X, Low K-H, Alexander A, et al. Cyclin E overexpression sensitizes triple-negative breast cancer to wee1 kinase inhibition. Clin Cancer Res. 2018;24(24):6594–6610.
   PubMed Web of Science ®Google Scholar
• Gray-Bablin J, Zalvide J, Fox MP, et al. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci U S A. 1996;93(26):15215–15220.
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A. 1993;90(3):1112–1116.
   PubMed Web of Science ®Google Scholar
• Nie L, Wei Y, Zhang F, et al. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019;10(1):5114.
   PubMedGoogle Scholar
• Zhao Z-M, Yost SE, Hutchinson KE, et al. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. BMC Cancer. 2019;19(1):96.
   PubMed Web of Science ®Google Scholar
• Sinn E, Muller W, Pattengale P, et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987;49(4):465–475.
   PubMed Web of Science ®Google Scholar
• Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell. 1984;38(3):627–637.
   PubMed Web of Science ®Google Scholar
• Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411(6841):1017–1021.
   PubMed Web of Science ®Google Scholar
• Geng Y, Yu Q, Whoriskey W, et al. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci U S A. 2001;98(23):13138–13143.
   PubMed Web of Science ®Google Scholar
• Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol. 1997;17(1):453–459.
   PubMed Web of Science ®Google Scholar
• Geng Y, Michowski W, Chick JM, et al. Kinase-independent function of E-type cyclins in liver cancer. Proc Natl Acad Sci U S A. 2018;115(5):1015–1020.
   PubMed Web of Science ®Google Scholar
• Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell. 2003;114(4):431–443.
   PubMed Web of Science ®Google Scholar
• Parisi T, et al. Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. Embo J. 2003;22(18):4794–4803.
   PubMed Web of Science ®Google Scholar
• Bishop AC, Shah K, Liu Y, et al. Design of allele-specific inhibitors to probe protein kinase signaling. Curr Biol. 1998;8(5):257–266.
   PubMed Web of Science ®Google Scholar
• Bishop AC, Ubersax JA, Petsch DT, et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature. 2000;407(6802):395–401.
   PubMed Web of Science ®Google Scholar
• Schraml P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003;200(3):375–383.
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347(20):1566–1575.
   PubMed Web of Science ®Google Scholar
• Zhao Z-M, Yost SE, Hutchinson KE, et al. CCNE1 amplification is associated with poor prognosis in patients with triple-negative breast cancer. BMC Cancer. 2019;9(1):96.
   Google Scholar
• Porter DC, Zhang N, Danes C, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol. 2001;21(18):6254–6269.
   PubMed Web of Science ®Google Scholar
• Wingate H, Zhang N, McGarhen MJ, et al. The tumour-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem. 2005;280(15):15148–15157.
   PubMed Web of Science ®Google Scholar
• Spruck CH, Won K-A, Reed SI, et al. Deregulated cyclin E induces chromosome instability. Nature. 1999;401(6750):297–300.
   PubMed Web of Science ®Google Scholar
• Teixeira LK, Wang X, Li Y, et al. Cyclin E deregulation promotes loss of specific genomic regions. Curr Biol. 2015;25(10):1327–1333.
   PubMed Web of Science ®Google Scholar
• Hunt KK, Karakas C, Ha MJ, et al. Cytoplasmic cyclin E predicts recurrence in patients with breast cancer. Clin Cancer Res. 2017;23(12):2991–3002.
   PubMed Web of Science ®Google Scholar
• Etemadmoghadam D, George J, Cowin PA. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One. 2010;5(11):e15498.
   PubMed Web of Science ®Google Scholar
• Akli S, et al. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 2011;71(9):3377–3386.
   PubMed Web of Science ®Google Scholar
• Sonntag R, Giebeler N, Nevzorova YA, et al. Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. Proc Natl Acad Sci USA. 2018;115(37):9282–9287.
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003;3:233–245.
   PubMed Web of Science ®Google Scholar
• Au-Yeung G, Lang F, Azar WJ, et al. Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin Cancer Res. 2017;23(7):1862–1874.
   PubMed Web of Science ®Google Scholar
• Du, Du J, Widlund HR, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004;6:565–576.
   PubMed Web of Science ®Google Scholar
• Koff A, Cross F, Fisher A, et al. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell. 1991;66(6):1217–1228.
   PubMed Web of Science ®Google Scholar
• Aleem E, Hirokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005;7(8):831–836.
   PubMed Web of Science ®Google Scholar
• Geisen C, Moroy T. The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. J Biol Chem. 2002;277(42):39909–39918.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Maller JL. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Science. 2004;306:885–888.
   PubMed Web of Science ®Google Scholar
• Geng Y, et al. Kinase-independent function of cyclin E. Mol Cell. 2007;25(1):127–139.
   PubMed Web of Science ®Google Scholar
• Sweeney KJ, Swarbrick A, Sutherland RL, et al. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene. 1998;16(22):2865–2878.
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2016;16:101–114.
   PubMed Web of Science ®Google Scholar